GeneHealth - Your precision medicine

Lobomycosis

Disease Details

Family Health Simplified

Buy Membership

Description: Lobomycosis is a chronic fungal skin infection caused by the yeast-like organism Lacazia loboi, characterized by keloid-like nodules on the skin.
Type: Lobomycosis is an infectious disease. It is not genetically transmitted; it is caused by the fungus *Lacazia loboi*.
Signs And Symptoms: The disease is endemic in rural regions in South America and Central America. Infection most commonly develops after minor scratches or insect bites, but many patients cannot recall any skin trauma. Human-to-human transmission does not occur, and the disease is only acquired from the environment. The disease manifests as chronic keloidal nodular lesions on the ears, legs, or arms.
Diagnosis of Lobo's disease is made by taking a sample of the infected skin (a skin biopsy) and examining it under the microscope. Lacazia loboi is characterized by long chains of spherical cells interconnected by tubules. The cells appear to be yeast-like with a diameter of 5 to 12 μm. Attempts to culture L. loboi have so far been unsuccessful.
Prognosis: Lobomycosis, also known as Jorge Lobo's disease, is chronic and often progresses slowly. The prognosis for individuals with lobomycosis is generally poor because the infection is typically resistant to antifungal treatments. Surgical excision of the lesions may offer some relief; however, recurrence is common. The disease can cause significant disfigurement and may also lead to secondary infections. Long-term management aims to control symptoms and prevent complications.
Onset: The onset of lobomycosis, also known as Jorge Lobo's disease, is typically very slow and gradual. It can take several months or even years after initial exposure for symptoms to develop. The disease is characterized by chronic, localized skin infections resulting in nodules and plaques, primarily affecting exposed areas of the body such as the ears, limbs, and face.
Prevalence: Lobomycosis, also known as Jorge Lobo's disease, is a rare chronic fungal infection caused by the yeast-like organism *Lacazia loboi*. It is predominantly found in tropical regions of Central and South America. The disease primarily affects humans and dolphins, with most reported cases occurring in rural populations engaged in activities such as agriculture and fishing. The exact prevalence is not well-documented due to its rarity and the challenges in diagnosing the disease, but it is considered an uncommon condition even within its endemic areas.
Epidemiology: Lobomycosis is a chronic fungal infection primarily affecting the skin and subcutaneous tissues. It is caused by the dimorphic fungus *Lacazia loboi*. Here are key details about its epidemiology:

- **Geographical Distribution**: The disease is predominantly found in tropical and subtropical regions of South and Central America, especially in countries like Brazil, Colombia, Venezuela, and Guyana.
- **Affected Populations**: Lobomycosis primarily affects individuals in rural and forested areas. It is more common among people who have frequent contact with water, such as fishermen and farmers.
- **Environmental Reservoir**: The exact environmental reservoir remains unknown, but the fungus is believed to inhabit aquatic environments.
- **Transmission**: Direct contact with contaminated water or traumatic implantation of the fungus into the skin (e.g., through cuts and abrasions) are considered the primary modes of transmission.
- **Animal Hosts**: The disease has been observed in dolphins, suggesting zoonotic potential.

In summary, lobomycosis is a rare but geographically clustered disease affecting mainly rural populations in tropical regions.
Intractability: Yes, lobomycosis is considered intractable. It is a chronic fungal infection caused by the organism Lacazia loboi, and it is notoriously difficult to treat. The disease often requires surgical intervention as antifungal medications are typically ineffective.
Disease Severity: Lobomycosis is a chronic fungal infection that primarily affects the skin. It is most commonly seen in tropical and subtropical regions and is caused by the fungus *Lacazia loboi*. The disease is characterized by the presence of keloidal nodules, plaques, and ulcerations on the skin. While it can be disfiguring and affect the quality of life, it typically does not affect internal organs and is not considered life-threatening. However, the condition can be persistent and challenging to treat, requiring surgical removal of lesions or long-term antifungal therapy.
Healthcare Professionals: Disease Ontology ID - DOID:13026
Pathophysiology: Lobomycosis, also known as Jorge Lobo's disease, is a chronic fungal infection caused by the yeast-like organism Lacazia loboi.

### Pathophysiology
The disease primarily affects the skin and subcutaneous tissues. Lacazia loboi is introduced into the body through minor cuts or abrasions, often in humid, tropical environments. Once inside the body, the fungus induces a granulomatous inflammatory response. It typically presents as keloid-like nodules or plaques on the skin, which can coalesce over time. The infection spreads locally and can cause significant disfigurement but usually does not disseminate to internal organs. The immune response is often inadequate to clear the infection, leading to its chronic nature.

### Nan
There is currently no specific mention or established correlation between lobomycosis and nanoparticles (nan). The term "nan" does not apply to the context of lobomycosis.
Carrier Status: Lobomycosis is not known to have a carrier state. It is an infection caused by the fungus *Lacazia loboi* and primarily affects humans and dolphins, typically in the form of chronic skin lesions.
Mechanism: Lobomycosis is a chronic granulomatous fungal infection caused by the pathogen *Lacazia loboi*. The mechanism of the disease involves the pathogen entering the skin, typically through traumatic inoculation. Once in the body, the fungus induces a chronic inflammatory response, leading to the formation of granulomas, which are clusters of immune cells formed in an attempt to contain the infection.

The molecular mechanisms underlying lobomycosis are not fully understood, largely due to the difficulty in culturing *L. loboi* in laboratory settings. However, it is known that the fungal cells induce an immune response that features chronic inflammation. The pathogen appears to resist destruction by the host's immune system, contributing to the persistence and chronicity of the lesions. The granulomas are composed mainly of macrophages, multinucleated giant cells, and lymphocytes, indicative of the host's prolonged immune response trying to wall off the pathogen.

Further research is needed to elucidate the specific molecular pathways and virulence factors of *L. loboi* that facilitate its persistence and the associated immune response.
Treatment: Surgical excision or cryosurgery is the treatment of choice. Treatment with antifungals has been considered ineffective, but the use of clofazimine and dapsone in patients with leprosy and lobomycosis has been found to improve the latter. This treatment regimen, with concomitant itraconazole, has been used to prevent recurrence after surgery.
Compassionate Use Treatment: Lobomycosis, caused by the fungus *Lacazia loboi*, is notoriously difficult to treat with standard antifungal medications. For compassionate use or experimental treatments, the following have been explored with varying degrees of success:

1. **Surgical Excision**: This is often the primary approach and involves removing the affected tissue.

2. **Clofazimine**: Originally an anti-leprosy drug, it has been used off-label for lobomycosis with some reported success.

3. **Itraconazole and Terbinafine**: These antifungal medications have been tried, though their effectiveness is inconsistent.

4. **Cryotherapy**: Applying extreme cold to destroy affected tissues has been used experimentally.

5. **Immunotherapy**: Enhancing the patient's immune response to combat the infection has been proposed but is still in experimental stages.

Patients with lobomycosis should ideally be managed by a team of specialists familiar with the condition due to its complexity and treatment challenges.
Lifestyle Recommendations: Lobomycosis is a chronic fungal infection caused by the pathogen *Lacazia loboi*. Here are some lifestyle recommendations for managing and preventing lobomycosis:

1. **Avoiding Contaminated Waters**: Limit exposure to freshwater environments known to harbor *Lacazia loboi*, primarily in endemic areas such as the Amazon Basin.

2. **Protective Clothing**: Wear protective clothing, including gloves and long sleeves, when engaging in activities that involve potential contact with contaminated water or soil.

3. **Skin Hygiene**: Maintain good skin hygiene, especially after contact with potentially contaminated water. Clean and disinfect any cuts or abrasions promptly.

4. **Regular Medical Check-Ups**: Periodically visit a healthcare provider for skin examinations, especially if living or traveling in endemic regions.

5. **Footwear**: Use protective footwear to avoid direct contact with soil and water in endemic regions.

6. **Education**: Educate yourself and others about the risk factors and preventive measures associated with lobomycosis if living in or visiting high-risk areas.

These measures can help reduce the risk of contracting lobomycosis and aid in its management if already infected.
Medication: Lobomycosis, also known as Jorge Lobo's disease, is a chronic fungal infection caused by *Lacazia loboi*. Treatment is challenging and there are no specific antifungal medications proven to be consistently effective. Surgical excision of lesions is often the primary treatment approach, but recurrence is common. Alternative treatments like clofazimine and itraconazole have been used with variable success. Close monitoring and follow-up care are essential.
Repurposable Drugs: As of now, there are no well-established repurposable drugs for lobomycosis. Lobomycosis, caused by the fungus Lacazia loboi, typically requires surgical excision for treatment. Antifungal drugs have generally shown limited effectiveness. Research is ongoing to find better therapeutic options.
Metabolites: Lobomycosis is a chronic fungal infection of the skin and subcutaneous tissues, caused by the fungus Lacazia loboi. There's limited information on specific metabolites produced by Lacazia loboi, since the pathogen is not easily cultured and studied in laboratory conditions. Consequently, data on its metabolic processes and products remain relatively sparse. Researchers continue to explore this area to better understand the organism's biology and potential treatments.
Nutraceuticals: Lobomycosis, a chronic fungal infection caused by *Lacazia loboi*, primarily affects the skin and subcutaneous tissues. There is currently no established evidence supporting the use of nutraceuticals (dietary supplements with health benefits) for the treatment of lobomycosis. Management typically involves surgical excision and antifungal therapy. Therefore, nutraceuticals are not considered a standard or effective treatment for lobomycosis.
Peptides: Lobomycosis is a chronic fungal infection caused by the species Lacazia loboi. There is no specific information related to peptides or nanotechnology (nan) in the treatment or research concerning lobomycosis directly. The standard approach to this disease mainly involves surgical excision of the lesions, sometimes combined with antifungal medications. Advanced research might look into nanotechnology or peptides, but as of now, they are not standard in lobomycosis treatment.